Bradford C. Sippy
Chairman and Chief Executive Officer
Mr. Sippy founded Tremeau Pharmaceuticals in July 2016. He brings over 25 years of pharmaceutical industry experience across multiple therapeutic areas. He most recently served as Vice President and Head of U.S. Marketing for Sunovion Pharmaceuticals, where he oversaw all in-line, late stage, and new product planning activities for Sunovion’s entire US portfolio, including P&L responsibility for the blockbuster drugs LATUDA and LUNESTA. Previously to this he established and served as the head of Sunovion’s Neurology Business Unit, overseeing all commercial activities for the launch of the anti-epileptic APTIOM for its initial and follow-on indications.
Prior to joining Sunovion Mr. Sippy held various roles of increasing responsibility in manufacturing, managed markets, sales, market research, and marketing at Merck Inc. and Roche Pharmaceuticals. This experience includes nearly ten years working on non-selective and COX-2 selective NSAIDs, including TORADOL (ketorolac tromethamine), VIOXX (rofecoxib), and ARCOXIA (etoricoxib).
Among his commercial achievements, Mr. Sippy was named a Top 25 U.S. Marketer in 2012 by Parade Magazine and won the 2013 MM&M Gold Award for Best Multi-Channel Campaign, both in recognition for the creation of FOLLOW THE WINGS, the first and only PhRMA Code compliant reminder ad.
Prior to starting in the pharmaceutical industry Mr. Sippy worked for DuPont, where he pioneered a process that reduced the hazardous waste emissions of DuPont's largest site by over 70%. For his contributions to the environment, Mr. Sippy was recognized by Edgar J. Woolard, CEO of DuPont, with the 1994 Environment Excellence Award.
Mr. Sippy holds a bachelors of science with honors in Chemical Engineering from Purdue University and an MBA, cum laude, from the Stern School of Business at New York University. He is also a licensed patent agent and admitted to practice before the US Patent and Trademark office.